Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher
Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.
The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.
Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.
This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.
FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.
The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.
Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.
This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.